TOG Review (RCOG Journal)
MRCOG Part 2
Sexual and Reproductive Health
Intrauterine contraception
Key Statistics
- 9% — UK women using IUC (community services)
- 0.2% — LNG-IUS unintended pregnancy, 12 months
- 2/1000 — Uterine perforation rate at insertion
Don't-miss facts
-
MHRA: prescribe LNG-IUS by brand name – licences differ (Mirena/Levosert 52 mg vs Jaydess 13.5 mg vs Kyleena 19.5 mg)
-
Current breast cancer = UKMEC 4 (absolute contraindication); past breast cancer <5 yr = UKMEC 3
-
Cu-IUD = most effective EC, only method effective after ovulation; fit ≤5 days post-UPSI or ≤day 19 of cycle
-
Perforation 2/1000 (×6 if breastfeeding postpartum); expulsion ~1 in 20, mostly first 3 months
-
Cervical shock: bradycardia 1.8%/hypotension 2.1%; if HR <40 bpm sustained → atropine 500–600 µg IV
-
Postpartum insertion ≤48h (incl. at LSCS): no ↑perforation but ↑expulsion; thread check at 6 weeks
-
52-mg LNG-IUS first-line for HMB and for endometrial hyperplasia without atypia (≥6 months, off-licence)
-
Device 1–2 cm from fundus may be left in situ per FSRH; not seen on USS ≠ expulsion – X-ray to exclude perforation first
Device quick-reference
Mirena 52mg – 5yr contra/HMB, 4yr endo protection Levosert 52mg – 6yr contra, 5yr HMB, no endo licence
Jaydess 13.5mg – 3yr contra only Kyleena 19.5mg – 5yr contra only Cu-IUD 380mm² T-frame – up to 10yr
Abbreviation Key
- IUC — intrauterine contraception
- FSRH — Faculty of Sexual and Reproductive Healthcare
- IUD/IUCD — intrauterine device / intrauterine contraceptive device LoC
- IUT — Letter of Competence in Intrauterine Techniques
- LNG-IUS — levonorgestrel-containing intrauterine system
- PID — pelvic inflammatory disease
- Cu-IUD — copper intrauterine device
- STI — sexually transmitted infection
- LARC — long-acting reversible contraception
- EC — emergency contraception
- HMB — heavy menstrual bleeding
- UPSI — unprotected sexual intercourse
- PMS/PMDD — premenstrual syndrome / premenstrual dysphoric
- BASHH — British Association for Sexual Health and HIV disorder
- hCG — human chorionic gonadotrophin
- MHT — menopausal hormone therapy
- DMPA — depot-medroxyprogesterone acetate
- UKMEC — UK Medical Eligibility Criteria for Contraceptive Use
Source: Ritchie J, Phelan N, Briggs P. Intrauterine contraception. The Obstetrician & Gynaecologist 2021;23:187–195. doi:10.1111/tog.12743
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).